GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

Chronic kidney disease is a common complication for people living with ... The new indications, approved Tuesday by the FDA, ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

The FDA's decision means Ozempic can now be used to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in patients with both chronic kidney disease ...

The FDA’s new approval makes the drug the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease. "Chronic kidney disease is very serious and common in patients ...

Chronic kidney disease is a common complication for people ... The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest set ...